Walleye Capital
VRTX icon

Walleye Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Walleye Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.7M Buy
30,752
+15,778
+105% +$7.36M 0.06% 291
2025
Q4 		$6.79M Buy
14,974
+12,512
+508% +$5.39M 0.02% 918
2025
Q3 		$964K Buy
2,462
+2,130
+642% +$890K ﹤0.01% 2123
2025
Q2 		$148K Sell
332
-3,071
-90% -$1.42M ﹤0.01% 3568
2025
Q1 		$1.65M Buy
3,403
+3,225
+1,812% +$1.5M 0.01% 1566
2024
Q4 		$71.7K Sell
178
-5,203
-97% -$2.41M ﹤0.01% 4254
2024
Q3 		$2.5M Buy
5,381
+2,596
+93% +$1.25M 0.01% 1737
2024
Q2 		$1.31M Sell
2,785
-54
-2% -$23.4K ﹤0.01% 2559
2024
Q1 		$1.19M Sell
2,839
-9,416
-77% -$3.98M ﹤0.01% 2422
2023
Q4 		$4.99M Sell
12,255
-14,090
-53% -$5.21M 0.01% 1115
2023
Q3 		$9.16M Buy
+26,345
New +$9.21M 0.02% 623
2023
Q2 		– Sell
-9,328
Closed -$3.14M – 4926
2023
Q1 		$2.94M Sell
9,328
-46,509
-83% -$13.9M 0.04% 511
2022
Q4 		$16.1M Sell
55,837
-11,186
-17% -$3.41M 0.29% 60
2022
Q3 		$19.4M Buy
67,023
+37,649
+128% +$10.8M 0.37% 32
2022
Q2 		$8.28M Buy
29,374
+16,634
+131% +$4.45M 0.23% 91
2022
Q1 		$3.33M Sell
12,740
-18,463
-59% -$4.38M 0.09% 237
2021
Q4 		$6.85M Buy
31,203
+2,373
+8% +$461K 0.21% 98
2021
Q3 		$5.23K Sell
28,830
-2,601
-8% -$508K 0.15% 84
2021
Q2 		$6.34K Buy
31,431
+29,963
+2,041% +$6.27M 0.22% 59
2021
Q1 		$315 Buy
+1,468
New +$322K 0.02% 734
2020
Q4 		– Sell
-3,428
Closed -$933K – 1121
2020
Q3 		$933K Buy
+3,428
New +$946K 0.1% 255
2020
Q2 		– Sell
-3,818
Closed -$908K – 984
2020
Q1 		$908K Buy
3,818
+1,598
+72% +$367K 0.2% 140
2019
Q4 		$486K Buy
2,220
+1,750
+372% +$354K 0.03% 679
2019
Q3 		$80K Buy
470
+190
+68% +$33.6K ﹤0.01% 1493
2019
Q2 		$51K Sell
280
-110
-28% -$19.2K 0.01% 1379
2019
Q1 		$72K Buy
+390
New +$72K 0.01% 1121

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Walleye Capital's VRTX Position: Q1 2026 in Review

Walleye Capital increased its Vertex Pharmaceuticals (VRTX) stake by 105% in Q1 2026, buying an estimated $7.36M and bringing the position to 30,752 shares worth $13.7M. The position accounts for 0.06% of the portfolio, ranked #291.

Walleye Capital first reported a position in VRTX in Q1 2019 and has held it in 26 quarters since. The position peaked at $19.4M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Walleye Capital held 30,752 shares of Vertex Pharmaceuticals worth $13.7M as of Q1 2026.
  • Walleye Capital bought 15,778 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.36M.
  • Vertex Pharmaceuticals made up 0.06% of Walleye Capital's portfolio in Q1 2026, its #291 holding.
  • Walleye Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 26 quarters since.
  • Walleye Capital's Vertex Pharmaceuticals position peaked at $19.4M in Q3 2022.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.